Reports
Publicerat: 2018-10-23 08:11:55
THIRD QUARTER (JULY-SEPTEMBER 2018) PERIOD (JANUARY-SEPTEMBER 2018) SIGNIFICANT EVENTS IN THE THIRD QUARTER SIGNIFICANT EVENTS DURING THE PERIOD SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD Working capital Acid-test ratio Equity/assets ratio Earnings per share before dilution Average number of shares Lars Hedbys, CEO Idogen AB Tel: +46 (0)46-275 63 30 E-mail: lars.hedbys@idogen.comInterim report 1 January-30 September 2018
CONDENSED EARNINGS AND CASH FLOW
(Amounts in KSEK unless otherwise stated)
2018
2017
2018
2017
2017
3 months
3 months
6 months
6 months
12 months
Jul-Sep
Jul-Sep
Jan-Sep
Jan-Sep
Jan-Dec
Net sales
0
0
0
0
0
Operating expenses
-7,268
-6,075
-23,065
-14,010
-21,299
Operating loss
-7,268
-6,075
-23,065
-14,010
-21,299
Loss for the period after net financial items
-7,318
-6,068
-22,828
-14 007
-21,322
Average number of shares
20,781,790
19,476,485
20,779,833
14,667,123
16,207,516
Average number of warrants
8,555,883
14,507,802
12,880,835
4,889,076
7,969,864
Loss per share before dilution (SEK)
-0.35
-0.31
-1.10
-0.95
-1.32
Loss per share after dilution (SEK)
-0.35
-0.31
-1.10
-0.95
-1.32
Cash flow from operating activities
-6,860
-7,510
-9,961
-11,657
-19,906
KEY FIGURES
Working capital
8,532
43,836
8,532
43,836
33,894
Acid-test ratio (%)
151
981
151
981
895
Equity/assets ratio (%)
51
90
51
90
90
Loss per share before dilution
-0.35
-0.31
-1.10
-0.95
-1.32
Average number of shares
20,781,790
19,476,485
20,779,833
14,667,123
16,207,516
Definitions of Key Figures
Total current assets (including cash and cash equivalents) less current liabilities.
Total current assets (including cash and cash equivalents) relative to current liabilities.
Shareholders’ equity in relation to balance sheet total.
Profit after tax divided by the average number of shares for the period.
The average number of shares on the day when the new issue is registered.
This is an English version of the original Swedish report communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This information is such that Idogen AB is obligated to publish under the EU Market Abuse Regulation (MAR) and the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, on October 23 2018.
For additional information, please contact:
Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. Idogen’s most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company´s second project IDO T is developed to prevent kidney transplant rejection. In a third project, IDO AID, Idogen focuses on the treatment of autoimmune diseases. The treatment is based on the patient"s own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit www.idogen.com